{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-024446","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.176126+00:00","generated_at":"2026-05-24T15:16:25.398529+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Cellectar amends CEO/COO severance, reduces stockholder quorum to one-third","bullets":["Board on March 12, 2025 approved enhanced severance for CEO and COO upon qualifying termination after a change in control.","CEO James V. Caruso gets 24 months base salary, target bonus, and benefit continuation.","COO Jarrod Longcor gets 18 months base salary and benefit continuation.","On March 11, 2025, Board adopted amended Bylaws reducing stockholder quorum from a majority to one-third of shares.","Bylaws also revise procedural requirements for stockholder nominations and other business, and align with Delaware law."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-024446","json":"https://secwatch.observer/filing/0001104659-25-024446.json","markdown":"https://secwatch.observer/filing/0001104659-25-024446.md","text":"https://secwatch.observer/filing/0001104659-25-024446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925024446/0001104659-25-024446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925024446/tm259506d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T15:16:25.398529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e423c66a60f6e71ffc023f1116503f57c1c0ae8a","claim":"Cellectar Biosciences, Inc.: Amended and restated by-laws to align with Delaware law, revise director nomination procedures, and change quorum requirement from majority to one-third of shares (effective 2025-03-11).","evidence_excerpt":"On March 11, 2025, the Board adopted the Amended and Restated By-Laws of the Company (the \" By-Laws \"), effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925024446/0001104659-25-024446-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-03-11"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}